Cody Palmer
Overview
Explore the profile of Cody Palmer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cherif A, Ovcinnikova O, Palmer C, Engelbrecht K, Reuschenbach M, Daniels V
JAMA Netw Open
. 2024 Oct;
7(10):e2437703.
PMID: 39365579
Importance: Patients who have been treated for high-grade cervical intraepithelial neoplasia (CIN grade ≥2) are at a high risk for subsequent CIN and other cancers and diseases related to human...
2.
Palmer C, Morais E, Tota J
Viruses
. 2024 Aug;
16(8).
PMID: 39205257
Juvenile- and adult-onset recurrent respiratory papillomatosis (JORRP and AORRP) are rare but serious conditions that are caused by oral human papillomavirus (HPV) infections. The proliferation of wart-like growths throughout the...
3.
Diakite I, Martins B, Owusu-Edusei K, Palmer C, Patterson-Lomba O, Gomez-Lievano A, et al.
Infect Dis Ther
. 2024 Apr;
13(5):965-990.
PMID: 38589763
Human papillomavirus (HPV) is a common sexually transmitted virus that can cause cervical cancer and other diseases. Dynamic transmission models (DTMs) have been developed to evaluate the health and economic...
4.
Palmer C, Dolk C, Sabale U, Wang W, Saxena K
Expert Rev Vaccines
. 2024 Feb;
23(1):312-323.
PMID: 38417025
Background: A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed. Research Design And Methods: We compared the public health and...
5.
Palmer C, Tobe K, Negishi Y, You X, Chen Y, Abe M
J Med Econ
. 2023 Nov;
26(1):1546-1554.
PMID: 37962015
Objective: To assess the public health impact and cost effectiveness of gender-neutral vaccination (GNV) versus female-only vaccination (FOV) with human papillomavirus (HPV) vaccination in Japan. Methods: We modeled the public...
6.
Diakite I, Nguyen S, Sabale U, Pavelyev A, Saxena K, Tajik A, et al.
J Med Econ
. 2023 Aug;
26(1):1085-1098.
PMID: 37608730
Aim: The objective of this study was to estimate and compare the cost-effectiveness of switching from a bivalent to a nonavalent human papillomavirus (HPV) vaccination program in Norway, incorporating all...
7.
Owusu-Edusei K, Palmer C, Ovcinnikova O, Favato G, Daniels V
J Health Econ Outcomes Res
. 2022 Jul;
9(1):140-150.
PMID: 35795155
The United Kingdom (UK) switched from using the 4-valent human papillomavirus (HPV) vaccine (Gardasil®) to the 9-valent vaccine (Gardasil 9®) in 2021. To estimate and compare the health and economic...
8.
Daniels V, Prabhu V, Palmer C, Samant S, Kothari S, Roberts C, et al.
Hum Vaccin Immunother
. 2021 Jan;
17(7):1943-1951.
PMID: 33427033
The Advisory Committee on Immunization Practices (ACIP) recommended catch-up 9-valent Human Papillomavirus (HPV) vaccination through age 26 years, and shared clinical decision-making for adults aged 27-45 years, compared with catch-up...
9.
Castano M, Ndeffo-Mbah M, Rock K, Palmer C, Knock E, Mwamba Miaka E, et al.
PLoS Negl Trop Dis
. 2020 Jan;
14(1):e0007976.
PMID: 31961872
Since the turn of the century, the global community has made great progress towards the elimination of gambiense human African trypanosomiasis (HAT). Elimination programs, primarily relying on screening and treatment...
10.
Rock K, Ndeffo-Mbah M, Castano S, Palmer C, Pandey A, Atkins K, et al.
Clin Infect Dis
. 2018 Jun;
66(suppl_4):S286-S292.
PMID: 29860287
Background: Control of gambiense sleeping sickness relies predominantly on passive and active screening of people, followed by treatment. Methods: Mathematical modeling explores the potential of 3 complementary interventions in high-...